Quantcast

Latest Peer M. Schatz Stories

2014-06-18 16:26:41

GERMANTOWN, Maryland, and HILDEN, Germany, June 18, 2014 /PRNewswire/ -- - Assay offers faster quantification of CMV DNA levels in patient samples - Up to 60% of all transplant patients are repeatedly tested for CMV viral load to help avoid potentially life-threatening conditions caused by this virus - PMA approval of artus(R) CMV RGQ MDx Kit adds further value to the QIAsymphony modular family of automated instruments as the...

2014-05-30 04:22:13

HILDEN, Germany, and GERMANTOWN, Maryland, May 30, 2014 /PRNewswire/ -- - Fourth oncology project with Lilly expands QIAGEN's Personalized Healthcare pipeline - Development of modular assay panels focuses on multiple biomarkers targeting cellular pathways associated with innovative cancer therapies under development by Lilly - Project to include assays for QIAGEN's new multi-modal, multi-analyte Modaplex...

2014-05-23 20:21:52

GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S. approval to guide use of Amgen's Vectibix(R) (panitumumab) in treatment of metastatic colorectal cancer - FDA approval (PMA) of therascreen KRAS RGQ PCR Kit for Vectibix expands QIAGEN's leadership in molecular companion diagnostics for personalized healthcare - QIAGEN driving the adoption of molecular tests...

2014-05-20 16:26:37

HILDEN, Germany and GERMANTOWN, Maryland, May 20, 2014 /PRNewswire/ -- - New biomedical content resources strengthen QIAGEN's industry-leading bioinformatics portfolio - Expansion will offer clinical researchers the most comprehensive, high-quality and up-to-date literature source for gene variant and disease phenotype associations - Expert-curated hereditary variants from HGMD are now available to customers using...

2014-05-05 16:27:10

GERMANTOWN, Maryland, and HILDEN, Germany, May 5, 2014 /PRNewswire/ -- - FDA clearance for QIAsymphony RGQ MDx, a complete sample-to-result automation platform, marks a milestone for one of QIAGEN's major global growth drivers - U.S. launch of artus C. difficile QS-RGQ MDx Kit will provide a reliable molecular test for a widespread healthcare-associated infection - QIAGEN continues to advance pipeline with additional FDA...

2014-04-10 16:24:24

HILDEN, Germany and VIENNA, April 10, 2014 /PRNewswire/ -- - Reliable diagnostic tools under development for mutations of calreticulin (CALR) are expected to benefit patients with blood disorders known as myeloproliferative neoplasms - QIAGEN acquired exclusive worldwide license for CALR biomarker from CeMM Vienna, whose researchers recently published the discovery in the New England Journal of...

2014-04-03 04:20:47

SAN DIEGO and HILDEN, Germany, April 3, 2014 /PRNewswire/ -- - New innovative product launches at American Association for Cancer Research (AACR) Annual Meeting add to broad portfolio of NGS solutions - High-speed QIAxpert accelerates quantification and quality control of nucleic acids with easy-to-use software and analysis aiding sample-to-insight workflows - CLC Cancer Research Workbench is the world's first...

2014-02-12 04:20:52

MARCO ISLAND, Florida and HILDEN, Germany, February 12, 2014 /PRNewswire/ -- - Significant expansion of 'universal' portfolio compatible with any NGS system includes several novel sample preparation products as well as solutions for clinical use - New bioinformatics solutions, including CLC Cancer Research Workbench and Ingenuity Clinical will accelerate analysis and interpretation of NGS data QIAGEN N.V. (NASDAQ:...

2014-01-29 16:28:20

VENLO, The Netherlands, January 29, 2014 /PRNewswire/ -- - Achieved 2013 targets: Adjusted net sales $1.31 billion (+5% CER), growth in all regions and customer classes; adjusted operating income $355.8 million; adjusted EPS $1.14 - Q4 2013 results: Adjusted net sales $362.6 million (+5% CER); adjusted operating income $106.3 million; adjusted EPS $0.36 - Ambition to build on 2013 progress to further accelerate innovation and...

2014-01-13 04:20:54

GERMANTOWN, Maryland, and HILDEN, Germany, January 13, 2014 /PRNewswire/ -- - Expanding collaboration to develop FDA-regulated diagnostics based on exosomes to measure gene mutations targeted by new anti-cancer therapies - Non-invasive detection of biomarkers from blood reduces patient risk and advances access to the benefits of personalized medicine - Automated biofluid-based molecular diagnostics have significant potential to...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.